GlycoMimetics, Inc. (NASDAQ:GLYC) Q3 2023 Earnings Conference Call November 3, 2023 8:30 AM ET

Company Participants

Christian Dinneen-Long - General Counsel

Harout Semerjian - Chief Executive Officer

Edwin Rock - Chief Medical Officer

Brian Hahn - Chief Financial Officer

Conference Call Participants

Roger Song - Jefferies

Boris Peaker - TD Cowen

Operator

Good morning, and thank you for joining the GlycoMimetics Q3 2023 Earnings Call. At this time, all participants are in a listen-only mode. Following management's remarks, we will hold a question-and-answer session. [Operator Instructions]

I would now like to turn the call over to Christian Dinneen-Long, Company Counsel at GlycoMimetics. Please go ahead.

Christian Dinneen-Long

Good morning. Today, we will review our business updates and financial results for the quarter ended September 30, 2023. The press release issued this morning is available on the company's website at glycomimetics.com. This call is being recorded. A dial-in phone replay will be available for 24 hours after the close of the call. The webcast replay will also be available for 30-days in the Investors section of the company's website.

Joining me on the call today from GlycoMimetics are Harout Semerjian, Chief Executive Officer; Brian Hahn, Chief Financial Officer; and Dr. Edwin Rock, Chief Medical Officer.

Today's call will include forward-looking statements based on our current expectations. Forward-looking statements may include, but are not limited to, statements about the company's product candidates, uproleselan and GMI-1687 along with statements about the progress and timing of clinical trials being conducted by us or our collaborators, planned or potential regulatory agency interactions or submissions, development plans and activities, prelaunch preparations, the company's cash position and runway and our expectations regarding data readouts from clinical trials.

Such statements represent management's judgment and intention as of today and involve assumptions, risks and uncertainties. GlycoMimetics undertakes no obligation to update or revise any forward-looking statement. For information concerning the risk factors that could affect the company, please refer to our filings with the SEC, which are available from the SEC or through the GlycoMimetics website.

I'll now turn the call over to Harout.

Harout Semerjian

Thank you, Christian, and good morning, everyone. In the third quarter, we continued to make strong progress advancing our clinical pipeline as we evolve into a commercial stage organization. We remain committed to executing on our vision to deliver uproleselan to AML patients in need of new treatment options, while we leverage our unique glycobiology approach to develop innovative medicines in additional diseases such as sickle cell.